Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT03775200 is registered in ClinicalTrials.gov with COMPASS Pathways as lead sponsor.

NCT NCT03775200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03775200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Lead sponsor
COMPASS Pathways
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2019
Completion date
September 27, 2021
Enrollment
233 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression